Martin A. Smith - 08 Feb 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Executive Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Martin A. Smith
Issuer symbol
IDXX
Transactions as of
08 Feb 2023
Net transactions value
$0
Form type
4
Filing time
10 Feb 2023, 16:04:15 UTC
Previous filing
06 Sep 2022
Next filing
16 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IDXX Common Stock 78 08 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award +5,316 5,316 08 Feb 2023 Common Stock 5,316 $497.43 Direct F2, F5
transaction IDXX Incentive Stock Option (right-to-buy) Award +201 201 08 Feb 2023 Common Stock 201 $497.43 Direct F3, F5
transaction IDXX Restricted Stock Unit Award +754 +61% 1,995 08 Feb 2023 Common Stock 754 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 35 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022 and December 31, 2022.
F2 Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024.
F3 Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027.
F4 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.
F5 Not applicable.